It is worth noting that POLE-mutated cases have shown a high rate of response to immunotherapy in tumors of other sites, such as colorectal and endometrial cancers [6,56,57], and as such, this should also be explored for PDAC. The gene discussed is POLE; the disease is endometrial cancer.